Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.
Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.
Pliant Therapeutics presented promising data on their drug bexotegrast at the EASL International Liver Congress. Key findings included positive interim results from the Phase 2a INTEGRIS-PSC trial, showing that bexotegrast was well tolerated and effective in reducing markers of liver fibrosis over 12 weeks. Additionally, bexotegrast demonstrated a unique mechanism of action in targeting fibrogenic cells and inhibiting TGF-β signaling. These results further validate bexotegrast's potential as a treatment for fibrotic liver disease.
Pliant Therapeutics presented key data on their drug bexotegrast at the American Thoracic Society 2024 International Conference. The data includes clinical safety, imaging, and preclinical results supporting late-stage development of the drug for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Dr. Gregory P. Cosgrove highlighted that bexotegrast has been well tolerated in over 700 participants across 15 trials with mostly mild to moderate adverse events. Dr. Mahru C. An shared that bexotegrast effectively targets TGF-beta signaling in fibrogenic cells. Dr. Martin L. Decaris reviewed a post-hoc analysis showing significant modulation of plasma biomarkers in IPF patients over 12 weeks. Lastly, Dr. Jonathan G. Goldin reported a reduction in lung fibrosis progression and no increase in alveolar inflammation in bexotegrast-treated patients over 24 weeks.
Pliant Therapeutics announced positive topline data from a 12-week Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF). The study showed that bexotegrast 160 mg led to a reduction in total lung collagen compared to an increase in the placebo group, suggesting potential reversal of fibrosis. Improvements in forced vital capacity (FVC) and reduced cough severity were observed in bexotegrast-treated patients at all timepoints. The drug was well tolerated with no serious adverse events or discontinuations. The trial involved 10 patients, with 7 receiving bexotegrast and 3 on placebo. PET imaging was used to measure changes in lung collagen levels. The primary endpoint was the change in standardized uptake value (SUV) of a PET ligand that binds to type 1 collagen. Bexotegrast-treated patients showed a reduction in SUV, indicating a decrease in lung collagen. Additionally, improvements in fibrosis biomarkers, FVCpp, and patient-reported cough severity were noted.
Pliant Therapeutics, Inc. (PLRX) announces two poster presentations at the EASL International Liver Congress in Milan, Italy. The presentations focus on the updated safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial and the TGF-beta inhibition in human liver explant tissue with biliary fibrosis. The company continues to lead in the discovery of novel therapeutics for fibrotic diseases.
Pliant Therapeutics, a leader in fibrotic disease therapeutics, reported positive safety and efficacy data from Phase 2a trials. They accelerated the BEACON-IPF Phase 2b trial and received regulatory clearance for the PLN-101325 muscular dystrophy program. Financially, they reported a net loss of $47.0 million, with $483.9 million in cash and investments as of March 31, 2024.
Pliant Therapeutics, a clinical-stage biotechnology company focusing on fibrotic diseases, will participate in investor events in May 2024. The events include discussions with key company executives, offering insights into the company's progress and future plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.